GEN Exclusives

More »

GEN News Highlights

More »
Feb 14, 2014

Fluidigm Broadens Single-Cell Focus with Completion of DVS Acquisition

  • With the closing of its DVS acquisition originally announced on January 29, Fluidigm adds a highly complementary single-cell protein analysis platform to its single-cell genomics platforms to create a portfolio of single-cell analyses technologies.

    DVS’s principal product is the CyTOF® 2 Mass Cytometer, which analyzes antibody/metal complexes using atomic mass spectrometry. The technology reportedly enables high-parameter single-cell protein analysis. Several members of DVS’ management, operations, and research and development teams—including co-founders Scott Tanner, Dmitry Bandura, and Vladimir Baranov—are joining Fluidigm to drive the integration of the organizations and support the continued growth of the combined business.

    “As evidenced by its products, technology, people, and business trajectory, DVS is an extraordinary company. We are thrilled to have it become part of Fluidigm,” said Gajus Worthington, Fluidigm president and CEO, said in a statement. “2013 was an incredible year for Fluidigm as we took our business and scientific influence to a new level. Now we are doubling our efforts to take our newly combined company and collective capabilities to new heights. Fluidigm now offers a comprehensive portfolio of genomic and proteomic solutions for this new and very exciting field of single-cell biology.”



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?